Amber Implants Completes Enrolment of First-In-Human Clinical Trial of its VCFix® Spinal System
The Hague, Netherlands, 11 June 2024: Amber Implants (‘Amber’ or ‘the Company’), an innovative medical technology company developing next-generation implants for spinal injuries, today announces that it has completed enrolment of its first-in-human clinical trial with its innovative VCFix® Spinal System. The VCFix® Spinal System is the first device that does not rely on bone cement for the treatment of vertebral compression fractures.
